Hohetor (DE)
{name}
{subtitle}
A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer
city
~35 mi. (Bad Harzburg, Germany, +144 more cities)
facility
GSK Investigational Site
condition
Endometrial Carcinoma
drug
carboplatin, +3 more drugs
drug type
chemotherapy, +2 more types
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer
city
~39 mi. (Eimersleben, Germany, +107 more cities)
facility
Urologische Arztpraxis in Eisleben - Dr. med. Ralf Eckert
condition
Prostate Adenocarcinoma
drug
abemaciclib, +2 more drugs
drug type
hormone therapy, +1 more type
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
city
~45 mi. (Hannover, Germany, +192 more cities)
facility
Gynäkologisch-Onkologische Praxis am Pelikanplatz
biomarker
ER Positive, +1 more biomarker
condition
Breast Carcinoma
drug
abemaciclib, +1 more drug
drug type
hormone therapy, +1 more type
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
city
~45 mi. (Hannover, Germany, +140 more cities)
facility
Medizinische Hochschule Hannover ( Site 0200)
condition
Hepatocellular Carcinoma
drug
lenvatinib, +2 more drugs
drug type
chemotherapy, +2 more types
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
city
~45 mi. (Hannover, Germany, +199 more cities)
facility
Medizinische Hochschule Hannover ( Site 0458)
condition
Hepatocellular Carcinoma
drug
pembrolizumab
drug type
immunotherapy
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
city
~45 mi. (Hannover, Germany, +207 more cities)
facility
Gynaekologisch-onkologische Praxis Hannover ( Site 1013)
biomarker
ER Positive, +1 more biomarker
condition
Breast Invasive Ductal Carcinoma
drug
cyclophosphamide, +6 more drugs
drug type
chemotherapy, +3 more types
Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
city
~45 mi. (Hannover, Germany, +137 more cities)
facility
Medizinische Hochschule Hannover ( Site 0405)
condition
Skin Squamous Cell Carcinoma
drug
pembrolizumab
drug type
immunotherapy
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) (MK-7902-010)
city
~45 mi. (Hannover, Germany, +127 more cities)
facility
KRH Klinikum Siloah ( Site 2103)
condition
Hypopharyngeal Squamous Cell Carcinoma, +3 more conditions
drug
lenvatinib, +1 more drug
drug type
immunotherapy, +1 more type
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-small Cell Lung Cancer
city
~45 mi. (Hannover, Germany, +151 more cities)
facility
GSK Investigational Site
condition
Non-Small Cell Lung Carcinoma
drug
niraparib, +1 more drug
drug type
immunotherapy, +1 more type